Stock Buzzer: Immucell Corp (NASDAQ:ICCC) Sentiment Up, Despite Downtrend

November 21, 2016 - By Darrin Black   ·   0 Comments

Stock Buzzer: Immucell Corp (NASDAQ:ICCC) Sentiment  Up,  Despite Downtrend

Sentiment for Immucell Corp (NASDAQ:ICCC)

Immucell Corp (NASDAQ:ICCC) institutional sentiment increased to 1.6 in 2016 Q2. Its up 0.10, from 1.5 in 2016Q1. The ratio is more positive, as 6 active investment managers started new or increased holdings, while 4 reduced and sold their holdings in Immucell Corp. The active investment managers in our partner’s database now own: 911,107 shares, down from 1.83 million shares in 2016Q1. Also, the number of active investment managers holding Immucell Corp in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 4 Increased: 6 New Position: 0.

ImmuCell Corporation is an animal health company. The company has a market cap of $27.71 million. The Firm operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. It has a 25.85 P/E ratio. The Firm has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

About 5,727 shares traded hands. ImmuCell Corporation (NASDAQ:ICCC) has declined 22.73% since April 19, 2016 and is downtrending. It has underperformed by 26.59% the S&P500.

According to Zacks Investment Research, “ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibody technology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.”

Healthinvest Partners Ab holds 0.53% of its portfolio in ImmuCell Corporation for 168,323 shares. Northpointe Capital Llc owns 253,502 shares or 0.21% of their US portfolio. Moreover, Perritt Capital Management Inc has 0.15% invested in the company for 82,579 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.08% in the stock. Minerva Advisors Llc, a Pennsylvania-based fund reported 14,559 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 2 insider purchases, and 2 insider sales for $11,811 net activity.

ICCC Company Profile

ImmuCell Corporation, incorporated on February 9, 1987, is an animal health company. The Firm operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Firm has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company’s lead product, First Defense, is manufactured from cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing its vaccine and milk protein purification technologies. The Company’s Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The Firm also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The Company’s product development initiative is Mast Out, a Nisin intramammary treatment of subclinical mastitis in lactating dairy cows.

Another recent and important ImmuCell Corporation (NASDAQ:ICCC) news was published by Quotes.Wsj.com which published an article titled: “Immucell Corp. ICCC (US: Nasdaq)” on February 11, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>